Psychedelic medicine pioneer exits MDMA biotech after regulatory blow

Psychedelic medicine pioneer, Rick Doblin, has left the MDMA biotech company, MAPS, following a regulatory setback. This decision comes after the FDA requested additional information for the Phase 3 trial of MDMA-assisted therapy for PTSD, delaying the study’s progress. Doblin’s departure from MAPS marks a significant development in the field of psychedelic medicine research.

Source link